AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 311 min read$TRDA

MPM BIOVENTURES 2018, L.P. sold $616K of TRDA (indirect holdings)

MPM BIOVENTURES 2018, L.P. sold 86,914 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.08 ($6.99–$7.20, $0.62M total) across 3 trades over 2026-08-27 to 2026-08-31. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).

Original reporting
SEC EDGAR · MPM BIOVENTURES 2018, L.P., MPM BioVentures 2018 LLC, MPM BioVentures 2018 GP LLC
Published Aug 31, 2026, 10:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 11:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TRDA
Neutral
medium confidence
Mentioned
$TRDA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TRDANeutralLow
01

Why it matters

The disclosed sale reduces insider ownership but is unlikely to affect market perception significantly.

02

Market read

Small insider sale with limited price impact; primarily of interest to shareholders tracking insider activity.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 5/10Novelty 4/10Timing: filing after market on 2026-08-31

Background

Form 4 filings provide transparency on insider holdings and trades.

Company-level read

Ticker impact

$TRDANeutralMedium confidence
Context

SEC Form 4 disclosed MPM BioVentures sold 86,914 shares of Entrada Therapeutics for $615,777, reducing its stake.

Expected impact

Potential slight downward pressure, unlikely to move price materially.

Evidence & confidence

Sale amount is under $1M and represents a small percentage of holdings; market impact limited.

Market effects

Sector

Minimal effect on biotech sector; typical insider transaction.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Insider may be reallocating capital, not necessarily negative for the company.

Key entities

  • Company
    Entrada Therapeutics, Inc.

    Biotech firm listed on NASDAQ under ticker TRDA.

  • Investor
    MPM BioVentures 2018, L.P.

    Insider reporting a 10% ownership stake.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TRDA insider trading history →

Related articles

OCT 14
$TRDAMed

Entrada Therapeutics Advances Duchenne Study To Highest Planned Dose Level

Entrada Therapeutics (TRDA) will test its Duchenne muscular dystrophy therapy, ENTR-601-44, at the highest planned dose (18 mg/kg) in its Phase 1/2 study after a favorable safety review. The study aims to evaluate safety, tolerability, and effectiveness in patients aged 4 to 20. Data from earlier cohorts are expected by the end of 2026 and early 2027.

rttnews.com1 min
OCT 14
$TRDAMedAI 9/10

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201…

Entrada Therapeutics, Inc. (TRDA) filed an SEC Form 8-K — Other Events. Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 -- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 m

SEC EDGAR 8-K2 min
OCT 14
$TRDAMedAI 8/10

Entrada reports phase 1/2 trial data for DMD therapy candidate

Entrada Therapeutics (TRDA) reported positive phase 1/2 trial data for ENTR-601-45 in Duchenne muscular dystrophy patients. The study met safety and tolerability goals, with treated patients showing increased dystrophin and exon skipping. Adverse events were mild. Cohort 2 data is expected in 2027. The company plans higher doses in subsequent cohorts.

investing.com2 min
OCT 14
$TRDAMedAI 8/10

Entrada receives clearance to test highest dose in DMD trial

Entrada Therapeutics (TRDA) advanced to the highest dose in its DMD trial after positive safety and pharmacokinetic data. The Phase 1/2 study, ELEVATE-44-201, is evaluating ENTR-601-44 for Duchenne muscular dystrophy. The company expects data from Cohort 1 by year-end 2026 and Cohort 2 in Q1 2027. ENTR-601-44 targets 8% of the global DMD patient population and received FDA Rare Pediatric Disease Designation in December 2025.

investing.com2 min